MD Stock Chart & Stats
$452.49
-$3.12(-0.68%)
At close: 4:00 PM EDT
$452.49
-$3.12(-0.68%)
Day’s Range― - ―
52-Week Range$240.12 - $467.41
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$37.65B
Enterprise Value$2.08K
Total Cash (Recent Filing)$328.97M
Total Debt (Recent Filing)$629.72M
Price to Earnings (P/E)12.7
Beta0.36
Next Earnings
Aug 04, 2026EPS Estimate
10.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding82,121,910
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.11
Price to Sales (P/S)0.95
P/FCF Ratio7.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$444.57Price Target Upside-1.75% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Cash GenerationSustained positive operating and free cash flow indicates the core clinical business converts earnings into liquidity reliably. This supports reinvestment, debt service and share repurchases, and provides a durable buffer against cyclical volume dips common in healthcare staffing models.
Profitability And ROE ReboundA meaningful recovery from prior losses to double-digit ROE shows improved operating leverage and capital efficiency. Lower relative leverage and regained profitability improve financial flexibility and make investments in growth or quality less dilutive over the medium term.
Physician-led Model And Service ExpansionA physician-led platform with hospital partnerships and breadth across maternal, neonatal and pediatric specialties creates sticky relationships and cross-sell opportunities. Investment in teleservices and data-enabled programs supports scalable growth and differentiation versus local competitors.
Bears Say
Stagnant/declining Revenue TrendA flat-to-down top line constrains the durability of margin and cash-flow improvements. Without steady organic volume growth or sizable, reliable acquisitions, the business must rely on pricing, RCM benefits or cost cuts to sustain earnings, increasing execution risk.
Rising Clinician Compensation CostsLabor is the primary cost in a clinician-staffing model; persistent wage inflation and staffing expense growth pressure operating margins. Given competitive clinician markets and hospital negotiation dynamics, higher compensation can be a structural headwind to margin sustainability.
Reliance On RCM/admin-fee TailwindsMaterial contribution from improved collections and admin fees boosts near-term pricing but is potentially transient. Dependence on RCM improvements and variable contract admin fees reduces revenue visibility and risks earnings if those one-off benefits reverse or normalize.
Pediatrix Medical Group News
MD FAQ
What was Pediatrix Medical Group, Inc.’s price range in the past 12 months?
Pediatrix Medical Group, Inc. lowest stock price was $240.12 and its highest was $467.41 in the past 12 months.
What is Pediatrix Medical Group, Inc.’s market cap?
Pediatrix Medical Group, Inc.’s market cap is $37.65B.
When is Pediatrix Medical Group, Inc.’s upcoming earnings report date?
Pediatrix Medical Group, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 6 days.
How were Pediatrix Medical Group, Inc.’s earnings last quarter?
Pediatrix Medical Group, Inc. released its earnings results on May 05, 2026. The company reported $7.682 earnings per share for the quarter, beating the consensus estimate of $6.635 by $1.048.
Is Pediatrix Medical Group, Inc. overvalued?
According to Wall Street analysts Pediatrix Medical Group, Inc.’s price is currently Overvalued.
Does Pediatrix Medical Group, Inc. pay dividends?
Pediatrix Medical Group, Inc. does not currently pay dividends.
What is Pediatrix Medical Group, Inc.’s EPS estimate?
Pediatrix Medical Group, Inc.’s EPS estimate is 10.32.
How many shares outstanding does Pediatrix Medical Group, Inc. have?
Pediatrix Medical Group, Inc. has 82,121,910 shares outstanding.
What happened to Pediatrix Medical Group, Inc.’s price movement after its last earnings report?
Pediatrix Medical Group, Inc. reported an EPS of $7.682 in its last earnings report, beating expectations of $6.635. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pediatrix Medical Group, Inc.?
Currently, no hedge funds are holding shares in MX:MD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pediatrix Medical Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$444.57 (-1.75% Downside)
$444.57 (-1.75% Downside)
Blogger Sentiment
Bullish
MX:MD Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $855.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.85%
Trailing 12-Months
Company Description
Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians. For pregnant individuals and their developing babies, Pediatrix provides comprehensive maternal-fetal medicine services in both clinical and inpatient settings, involving specialists such as maternal-fetal medicine physicians, obstetricians, and genetic counselors. Furthermore, the group delivers pediatric cardiology services, addressing both congenital and acquired heart conditions in patients ranging from the fetal stage through adulthood, under the care of dedicated pediatric cardiologists. Beyond these core areas, Pediatrix extends its expertise to various other pediatric subspecialties, including those requiring intensivists, surgeons, and ophthalmologists, and supplies vital support to hospital departments like emergency rooms and labor and delivery units. Established in 1979 in Sunrise, Florida, and formerly known as MEDNAX, Inc. until its renaming in July 2022, the company managed a network of approximately 2,700 physicians as of February 2022.
MD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a majority of positive operational and financial signals: strong Q1 adjusted EBITDA ($58M), above-expectation pricing growth (4%), improved collections (DSO down >5 days YoY), a solid cash balance, modest leverage (~1.3x), successful share repurchase, and strategic senior hires and partner-program rollout. Offsetting items include modest volume declines (NICU days down ~1%), rising clinical salary costs (+$9M S,W,B), higher Q1 cash usage ($130M vs $116M), and uncertainty around the sustainability of RCM-driven pricing and potential effects from tax subsidy lapses. Overall, positives materially outweigh the negatives, though management flagged areas to monitor (pricing tailwind fade, hospital pressures, and executive transition).View all MX:MD earnings summariesMD Stock 12 Month Forecast
Average Price Target
$444.57
▼(-1.75% Downside)